Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lots of buys flowing
They did R/S less than a year ago !!
MoneyTV with Donald Baillargeon, 8/7
Aug 07, 2015 05:00:00 (ET)
LOS ANGELES, Aug. 7, 2015 /PRNewswire/ -- Questions I'd Ask the President, mobile marketing, Hollywood, cannabis, vaping, credit repair, solar, mobile payments; this week on MoneyTV with Donald Baillargeon. MoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs, providing insights into their operations and outlooks for their futures.
Free information packages from the featured companies can be requested by sending an email to info@moneytv.net.
The television program can also be viewed online immediately at www.moneytv.net.
Featured companies on this week's program include:
Mega World Media Founder and CEO Travis Cloyd spoke of the exploding mobile marketing space and the Hollywood connection.
Singlepoint, Inc. (OTCPINK: SING) CEO Greg Lambrecht offered a progress report of their pending acquisition and investment offering.
XsunX, Inc. (OTCBB: XSNX) CEO Tom Djokovich said the company offers complete construction projects that include solar, citing carport complexes as an example.
Trycera Financial, Inc. (OTCBB: TRYF) CEO Ray Smith discussed their work with a non-profit organization.
Vapor Hub International, Inc. (OTCPINK: VHUB) CEO Kyle Winther said the company had recently experienced a record week of sales activity.
Pazoo, Inc. (OTCPINK: PZOO) CEO David Cunic announced they had leased space for a new cannabis testing lab in Portland, OR.
A complete menu of TV listings is available at the MoneyTV web site, http://www.moneytv.net.
MoneyTV Executive Producer and Anchor Donald Baillargeon is also the host of MoneyRap Radio, http://www.moneyrap.com and the daily television program Global Financial News Minute with Donald Baillargeon.
MoneyTV with Donald Baillargeon television program, Copyright MMXV, all rights reserved. MoneyTV does not provide an analysis of companies' financial positions and is not soliciting to purchase or sell securities of the companies, nor are we offering a recommendation of featured companies or their stocks. Information discussed herein has been provided by the companies and should be verified independently with the companies and a securities analyst. MoneyTV provides companies a 3 to 4 month corporate profile with multiple appearances for a cash fee of $11,995.00 to $17,250.00, does not accept company stock as payment for services, does not hold any positions, options or warrants in featured companies. The information herein is not an endorsement by Donald Baillargeon, the producer, publisher or parent company of MoneyTV.
Contact:
Donald Baillargeon
info@moneytv.net
949 388 5267
10Q next week ?
Pazoo, Inc. Signs Lease for Wholly-Owned Subsidiary, Harris Lee Holdings, LLC, in Portland, Oregon for New Lab Facility
Aug 06, 2015 09:30:00 (ET)
WHIPPANY, N.J., Aug. 6, 2015 /PRNewswire/ -- Pazoo, Inc. (OTC Pinks: PZOO) (German WKN#: A1J3DK), is pleased to announce that the company has signed a lease to secure a location for its Oregon testing lab facility.
Pazoo's Harris Lee management is very excited to have signed this lease and commenced meetings with the architect selected to begin the build out of the facility as soon as possible. Additionally, the Pazoo management team has also narrowed down several target states as strategic added locations for Harris Lee's next expansion phase.
Pazoo's management feels it is extremely important to move swiftly with this location since Measure 91 took effect last month in July. Measure 91 legalized recreational marijuana for people ages 21 and older, allowing adults over this age to possess up to eight ounces of "dried" marijuana and up to four plants. Additionally, the measure tasked the Oregon Liquor Control Commission with regulating sales of the drug. This measure will make the demand for testing even greater.
Pazoo CEO David Cunic commented, "We are very happy about securing a space in Portland and beginning the build-out of the facility. Our timing is impeccable as Governor Kate Brown has just signed into law that medical marijuana dispensaries may begin to sell marijuana for recreational use as early as October 1(st) of this year. Additionally, we have relationships with numerous growers in other states that we are in talks with who have additional operations in Oregon. These growers are looking for the same high quality testing that we will also be providing to them in other states as we continue to expand throughout the United States. The Oregon facility will help us solidify our footprint and exposure in the region. We are poised to begin generating revenue from our marijuana testing operations before the end of the year. Testing in Nevada (through MA & Associates, LLC) , Oregon (through Harris Lee Holdings, LLC) and Colorado (through our recent partnership with Harris Lee Colorado, LLC) are all expected to begin to be revenue sources for the company in the 4th quarter of this year which is right around the corner. These are truly exciting times for us."
Safe Harbor Statement:
This update includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as Pazoo, Inc. or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statement.
ABOUT PAZOO Inc.
Pazoo, Inc., is a company focused on health, wellness and safety. Our focus is to provide best-in-class laboratory testing of cannabis and cannabinoids to protect consumers from impurities, contaminants and other irregularities. Through our wholly-owned subsidiary, Harris Lee, and our partnership with MA & Associates, Pazoo provides industry-leading laboratory testing of cannabis. Harris Lee's and MA's license agreements with Steep Hill Labs, Inc. allows the Pazoo subsidiaries to use Steep Hill's top-rated testing protocols in select markets as we expand throughout the USA. Pazoo's subsidiaries are currently licensed to test cannabis in Nevada, Oregon and Colorado, with other states to come. Additionally, Pazoo delivers a comprehensive array of health and wellness information on its website www.pazoo.com.
ABOUT STEEP HILL LABS Inc.
Founded in California in 2008, Steep Hill is a science and technology firm that has become the industry leader in cannabis testing and analytics. With owned and licensed labs in four U.S. states and plans to add labs in New Mexico, Oregon and possibly Jamaica in 2015, Steep Hill is the largest cannabis lab network in the world. The company pioneered the first medical cannabis potency and microbiological contaminants testing methodology for use in California - the first state to legalize medical cannabis. Steep Hill has since developed a variety of revolutionary cannabis testing products, including QuantaCann(TM), QuantaCann2(TM) and GenKit(TM). Steep Hill provides expert consulting services to many states, countries and municipalities, and the company is developing proprietary genetic testing, mapping and trademark protection services for the industry as well.
Safe Harbor Statement:
This update includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as Pazoo, Inc. or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statement.
Picking up more shares today , all the way up to 0.01 ! IMO
Oooooopppppsssss ! News
Pazoo Wholly-Owned Subsidiary Harris Lee, LLC Signs Several Agreements With Harris Lee Colorado, LLC To Take Over An Existing Operational Marijuana Testing Lab In Denver, Colorado
Jul 28, 2015 09:30:00 (ET)
WHIPPANY, N.J., July 28, 2015 /PRNewswire/ -- Pazoo, Inc. (OTCPink Symbol: PZOO) (German WKN#: A1J3DK) is pleased to announce that wholly-owned subsidiary Harris Lee, LLC has signed a sublicense, and loan agreement with Harris Lee Colorado, LLC (HLC). These agreements now allow HLC to meet the in state residency requirement and provide for the necessary funding to take over the testing lab, expand the marketing and employment base and begin the expansion of the operations.
All agreements will be forwarded on to the Colorado MED for review. A small redesign of the layout of the laboratory will be undertaken to increase the efficiency and functionality of the facility. Over the past 2 months the Pazoo team has made contact with numerous growers and has gotten firm commitments from these growers to test with HLC once the State review is complete. This testing facility currently is using the Steep hill methodology and will continue to utilize this methodology moving forward under the license agreement signed between Harris Lee, LLC and Steep Hill Labs, Inc.
The Denver, Colorado facility is currently certified to provide potency testing. However, the process has already begun to achieve certification for the additional tests required in Colorado. This already revenue generating facility is expected to quickly expand the number and types of tests currently being conducted.
David Cunic, Co-CEO, states, "We are making the all-important move to a revenue growth stage company. There is a very strong foundation that has been created. We expect the Oregon lease to be finalized soon and we have already garnered strong interest for the products currently being distributed by CannabisKing. I want to thank the patience and support of our shareholders and I can now say with confidence that there is no limit to the success that will be achieved moving forward."
ABOUT PAZOO Inc.
Pazoo, Inc., is a company focused on health, wellness and safety. Our focus is to provide best-in-class laboratory testing of cannabis and cannabinoids to protect consumers from impurities, contaminants and other irregularities. Through our wholly-owned subsidiary, Harris Lee, and our partnership with MA & Associates, Pazoo provides industry-leading laboratory testing of cannabis. Harris Lee's and MA's license agreements with Steep Hill Labs, Inc. allows the Pazoo subsidiaries to use Steep Hill's top-rated testing protocols in select markets as we expand throughout the USA. Pazoo's subsidiaries are currently licensed to test cannabis in Nevada, Oregon and Colorado, with other states to come. Additionally, Pazoo delivers a comprehensive array of health and wellness information on its website www.pazoo.com.
ABOUT STEEP HILL LABS Inc.
Founded in California in 2008, Steep Hill is a science and technology firm that has become the industry leader in cannabis testing and analytics. With owned and licensed labs in four U.S. states and plans to add labs in New Mexico, Oregon and possibly Jamaica in 2015, Steep Hill is the largest cannabis lab network in the world. The company pioneered the first medical cannabis potency and microbiological contaminants testing methodology for use in California - the first state to legalize medical cannabis. Steep Hill has since developed a variety of revolutionary cannabis testing products, including QuantaCann(TM), QuantaCann2(TM) and GenKit(TM). Steep Hill provides expert consulting services to many states, countries and municipalities, and the company is developing proprietary genetic testing, mapping and trademark protection services for the industry as well.
Safe Harbor Statement:
This update includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as Pazoo, Inc. or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statement.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pazoo-wholly-owned-subsidiary-harris-lee-llc-signs-several-agreements-with-harris-lee-colorado-llc-to-take-over-an-existing-operational-marijuana-testing-lab-in-denver-colorado-300119628.html
SOURCE Pazoo, Inc.
/Web site: www.pazoo.com
(END) Dow Jones Newswires
July 28, 2015 09:30 ET (13:30 GMT)
Looks like Big News in the making ! And Very soon :)
Buys starting to flow again :) 490K
1/2 million shares buy @0.0062 !
0.0064 on the ASK ! quick run in the making !!
Lots of buys !
SeeThruEquity Initiates Coverage on BioCorRx Inc. with a Price Target of $0.13
NEW YORK, NY / ACCESSWIRE / July 22, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of BioCorRx Inc. (OTCQB: BICX) with a Price Target of $0.13.
The report is available here: BICX Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
With headquarters in Santa Ana, CA, BICX distributes and licenses the Start Fresh Program for alcoholism and opioid addiction to a growing network of clinics and addiction treatment centers across the country. BICX has begun to experience accelerating business trends of late, with the number of treatment centers that offer the Start Fresh Program(R) more than doubling over the last six quarters, which has also been a catalyst for rapid revenue growth. Indeed, since a rebranding of the company and a focus on growing by finding licensing and distribution partners, BICX has seen its top line rising quickly. Revenues grew by 111% YoY in 1Q15 after growing more than 60% from 2013 to 2014. We expect the company to continue these trends in 2015E, and view BICX as an intriguing, high risk / high reward enterprise in the specialized services subcategory of the health care industry.
“Given the multi-billion dollar market opportunity and even larger economic cost of treating alcohol and opioid substance abuse, as well as the lack of effective treatments in the current medical paradigm, we see a large opportunity for BICX as the company expands. With limited resources deployed to date, the company has more than doubled the number of clinics offering the Start Fresh Program in the last year while the number of patients undergoing the Start Fresh Program(R) treatment plan has risen by 402%. Considering the opportunity and apparent early traction garnered by the company, we see BICX as an intriguing, high risk / high reward enterprise in the specialized services subcategory of the health care industry.,” commented Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $0.13 per share.”
Additional highlights from the report are as follows:
Start Fresh Program achieving growing momentum
BICX has begun to experience accelerating business trends of late, with the number of licensed and contracted treatment centers offering the Start Fresh Program(R) more than doubling over the last six quarters, which has also been a catalyst for rapid revenue growth. Indeed, since a rebranding of the company and a focus on growing by finding licensing and distribution partners, BICX has seen its top line rising quickly with high margin revenue. Revenues grew by 111% YoY in 1Q15 after growing more than 60% from 2013 to 2014 – a year in which the company generated positive operating cash from operations. We expect BICX to continue its strong top line growth in 2015E as the company benefits from direct marketing efforts that spread awareness of the Start Fresh Program through campaigns in social media, TV, PR, and patient testimonials.
Alcoholism and opioid treatment a large and fragmented market
BICX’s Start Fresh Program(R) is a unique and proprietary approach to provide treatment for alcoholism and opioid addiction – two large and fragmented markets with ample room for growth and expansion. According to the Center for Diseases Control (CDC) there are over 38mn heavy drinkers in the United States. Indeed, the estimated market size for alcohol treatment is $22Bn per year, and the economic impact from heavy drinking is estimated at over $230Bn. Similarly, there are over 2mn Americans suffering from opioid addiction. There is a natural overlapping of end market applications for the Start Fresh Program(R), as opioids account for 18% alcohol treatment facility admissions.
Something is up for sure !!
Thinking about buying little more today !!
7/20/2015 Today !
BioCorRx, Inc. Chief Financial Officer, Lourdes Felix and Brady Granier, Chief Operating Officer and Interim Chief Executive Officer, Discuss Recent News in a New Audio Interview at SmallCapVoice.com
Jul 20, 2015 08:00:00 (ET)
BioCorRx, Inc. Chief Financial Officer, Lourdes Felix and Brady Granier, Chief Operating Officer and Interim Chief Executive Officer, Discuss Recent News in a New Audio Interview at SmallCapVoice.com
AUSTIN, Texas, July 20, 2015 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioCorRx, Inc. (OTCQB:BICX) developer of the Start Fresh Program (R) used for the treatment of alcohol and opioid dependence, announced today that a new audio interview is now available. The interview can be heard at http://smallcapvoice.com/blog/7-16-15-smallcapvoice-interview-with-biocorrx-inc-bicx
About SmallCapVoice.com
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html or sign up for our FREE newsletter here http://www.smallcapvoice.com/newsletter.html.
Visit BioCorRx, Inc.'s investor relations website at www.BICXcorp.com to receive the most up to date company information.
Click here to view Recent National Television Media on the BioCorRx YouTube Channel
Click here for company Facebook page for more stories and media coverage
About BioCorRx, Inc.
BioCorRx, Inc. (R) (BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh Program(R), a medication-assisted treatment program, consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program. For more information on BICX, visit www.BioCorRx.com
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
CONTACT: Investor Relations
SmallCapVoice.com, Inc.
512-267-2430
10Q ? Today ?
With the next news (which is very soon IMO) PZOO will pop over 0.01+ then may be pull back a little ...
I am buying now all the way to 0.008 for a good 25 -50 % profit ...
Guys ! Check it out .
http://m.wafb.com/wafb/db/346396/gallery/OzVntxgq
8K
Current Report Filing (8-k)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): June 30, 2015
BioCorRx Inc.
(Exact name of registrant as specified in its charter)
333-153381
(Commission File Number)
Nevada
26-0685980
(State or other jurisdiction of Incorporation)
(I.R.S. Employer Identification No.)
601 N. Parkcenter Drive, Suite 103
Santa Ana, California 92705
(Address of principal executive offices)
(714) 462-4880
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
Item 1.01 Entry Into a Material Definitive Agreement
On June 30, 2015, BioCorRx, Inc. (the “Company”), entered into an Asset Purchase Agreement (the “Agreement”) with Trinity Compound Solutions Inc. (“Trinity” or “Seller”) whereby the Company purchased the intellectual property and contractual rights of the Naltrexone Implant formula (“IP Asset”) created by Dr. Jim Rowe of Australia, with the option to purchase other formulas from Trinity. The purchase price for the IP Asset being purchased hereunder shall be one million dollars ($1,000,000), plus three million (3,000,000) common restricted shares of BioCorRx Inc., and a four year service agreement under which the President and owner of Trinity, as either an employee or consultant shall be compensated in an amount equal to $75,000 per annum including the bonus plan at the time the Agreement is executed. In consideration of the purchase price, Trinity sells, assigns, transfers and delivers to the Company, all of the Seller’s right, title, and interest in and to the copyrights, trademarks, patents, and other intellectual property rights worldwide, except for Australia and New Zealand, (“Territory”) and solely for use in the Territory. This IP Asset is used by a select compounding pharmacist trained to make the specific implant used in the Start Fresh Program. The above is a brief description of the Agreement and is qualified in its entirety by the full text of the Agreement, which is attached as Exhibit 10.1 this Current Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
Exhibit
Number
Description
10.1
Asset Purchase Agreement, dated June 30, 2015
99.1
Press Release, dated July 7, 2015
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOCORRX INC.
Date: July 7, 2015
By:
/s/ Lourdes Felix
Lourdes Felix
Chief Financial Officer and Director
3
YEEEEEEP ... Good one :)
BioCorRx, Inc. Finalizes Asset Purchase Agreement to Acquire Naltrexone Implant Formula for Treating Addiction
Jul 07, 2015 08:00:00 (ET)
BioCorRx, Inc. Finalizes Asset Purchase Agreement to Acquire Naltrexone Implant Formula for Treating Addiction
Los Angeles, July 7, 2015 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (BICX), developer of the Start Fresh Program(R) used for the treatment of alcohol and opioid dependence, announces the finalization of an asset purchase agreement with Trinity Compound Solutions (formerly Trinity Rx Solutions) ("Trinity") for its Naltrexone implant formula with an option to purchase other formulas from Trinity. The Company had previously entered into a letter of understanding (LOU) with Trinity for this agreement. This naltrexone pellet formula is used by a select compounding pharmacist trained to make the specific implant used in the Start Fresh Program. The Company currently has exclusive use rights to the implant in the U.S. and abroad (excluding Australia and New Zealand).
The particular naltrexone implant formula used to create the implant, which is a part of BioCorRx's Start Fresh Program, has been held as a trade secret by its original inventor and Trinity for approximately a decade. The implant has been used for several years by addiction specialists in Australia and is currently used by several addiction centers in the U.S. Any additional formulas owned by Trinity that the Company decides to acquire would be produced and marketed to treat their respective healthcare disorders.
As mentioned in a press release from the Company earlier this year, the Drug Quality and Security Act signed in November 2013, changed compounding laws. The law allows for the formation of a new type of compounding pharmacy called an "outsourcing facility". This type of pharmacy falls under federal oversight which would presumably result in greater patient safety. The new law was the result of a deadly meningitis outbreak caused by a New England compounding pharmacy in 2012. The Company intends to have the implant produced in an outsourcing facility which the company feels would give the implant wider acceptance within the medical community as well as with payors. Formula ownership also allows the Company to better evaluate and control the process of submitting the implant for FDA approval.
"This deal has been in the works for quite some time and we are very pleased to finally have an agreement in place. Trinity has been very patient with us as we focused on other aspects of our operation such as wider distribution establishment. We strongly believe that ownership of the formula and subsequent control over production of the naltrexone implant will bring down costs and streamline processing of orders, especially if produced in an outsourcing facility. While continuing our pursuit of widespread distribution of our program, we are also going to work with our consultants and advisors on developing a pathway for possible regulatory approval for the implant," stated COO and interim CEO Brady Granier.
Visit BioCorRx, Inc.'s investor relations website at www.BICXcorp.com to receive the most up to date company information.
Click here to view Recent National Television Media on the BioCorRx YouTube Channel
Click here for company Facebook page for more stories and media coverage
About BioCorRx, Inc.
BioCorRx, Inc. (R) (OTCQB: BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh Program(R), a medication-assisted treatment program, consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program. For more information on BICX, visit www.BioCorRx.com
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
CONTACT: Investor Relations
SmallCapVoice.com, Inc.
512-267-2430
BIOCORRX is Back .... NEWS 7/6/2015
BioCorRx, Inc. Announces First Patients Treated in Wellness Center Pilot Using the Start Fresh Program
Jul 06, 2015 08:00:00 (ET)
BioCorRx, Inc. Announces First Patients Treated in Wellness Center Pilot Using the Start Fresh Program
Los Angeles, July 6, 2015 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (BICX), developer of the Start Fresh Program, announces update on the Company's pilot program with Myriad Medical Marketing (MMM). The first location in the pilot program, Corona Physical Medicine (CPM), has just treated their first three patients using the Start Fresh Program. CPM is located at 1150 El Camino Avenue, Suite 108, Corona, CA 92879.
Upon successful completion of the pilot program, MMM will begin to introduce the Start Fresh Program to other wellness centers nationwide. The original plan was to run the pilot in up to five centers, however, MMM has since decided that resources would be better utilized by focusing on one center. "We are thrilled to see the first patients being treated using our program at Corona Physical Medicine. It took a little longer than anticipated to get the pilot program running due to the intense level of training and coordination required to ensure that each patient has a great and safe experience. This pilot program is a completely different distribution model than we are accustomed to, however, the overall potential is exciting should it be deemed viable by all parties involved," stated COO & interim CEO, Brady Granier.
CPM is a holistic wellness center owned by Dr. Jon Brunelle, founder of MMM. CPM's philosophy of integrative medicine can be highly beneficial to patients who undergo the Start Fresh Program. The center offers holistic medical services, delivered by medical doctors and other practitioners, which include chiropractic care, acupuncture, massage, nutrition, and hydration therapy among other services. "We are very pleased to have had treated our first few patients at Corona Physical Medicine. We plan to treat more in the coming weeks," stated Dr. Brunelle. "With all of Myriad's resources focused on the pilot program at our Corona location, we feel that we can better test and optimize the process before taking it to other locations. We are focused on creating a system that can be easily duplicated in other locations," added Dr. Brunelle.
Visit BioCorRx, Inc.'s investor relations website at www.BICXcorp.com to receive the most up to date company information.
Click here to view Recent National Television Media on the BioCorRx YouTube Channel
Click here for company Facebook page for more stories and media coverage
About BioCorRx, Inc.
BioCorRx, Inc. (R) (OTCQB: BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh Program(R), a medication-assisted treatment program, consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program. For more information on BICX, visit www.BioCorRx.com
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
CONTACT: Investor Relations
SmallCapVoice.com, Inc.
512-267-2430
Just did !
100% Agree with Pip611
Below 0.01 before end of day :(
Still Very Cheap PPS !!!
come on Baby lets mooooooooooooooooooooooove :)
UP WE GOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO :)
Level 2 ?
Moving Up Quickly
Above HOD ???? No way
Will close @ 0.02+ ..........
Already in and loaded :)
Need a lot of ASK hitting !
level 2 ?
Still here buddy ! Waiting for some news !
10 Q out ?
Level 2 ?
1.5 m ? That is nothing compared to the volume we had for the past couple of days ...
Hoping for no more to be added to ask side and let's move to the 9s ;)
Level 2 ?